6/3/2014 9:49:35 AM
CHICAGO--(BUSINESS WIRE)--MedImmune, the global biologics research and development arm of AstraZeneca, presented results today from its novel investigational immunotherapy portfolio, focusing on MEDI4736, at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. Overall, studies demonstrated durable clinical activity and tolerability for MEDI4736 across a range of tumor types.
Help employers find you! Check out all the jobs and post your resume.
comments powered by